Scandion Oncology announced that Dr. Maj Hedtjärn is appointed Chief Operating Officer (COO) and Head of R&D Operations in the company. Dr. Maj Hedtjärn will be leading the professional execution of Scandion Oncology's pipeline towards upcoming value inflection points starting with read out of the CORIST Phase II trial in Second Quarter 2021. She will ensure the implementation of strategy including rigor in planning, establishing excellence in processes to execute timelines in relation to existing and future pipeline. She will be central in establishing the basis for strategies for Scandion Oncology including market position analyses and work with the CEO and the board of directors on these matters. The new COO and Head of R&D Operations, Dr. Maj Hedtjärn is a seasoned life science executive with more than 15 years of R&D and leadership experience from both Scandinavian and international pharma and biotech (Lundbeck (DK), Santaris Pharma (DK) and Roche (CH)).